Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.

ABSTRACT:

Background

A Food and Drug Administration (FDA) safety communication in August 2011 warned that citalopram was associated with a dose dependent risk of QT prolongation and recommended dose restriction in patients over the age of 60 but did not provide data for this age group.

Methods

CitAD was a randomized, double-masked, placebo-controlled, multicenter clinical trial for agitation in Alzheimer's disease (AD). Participants were assigned to citalopram (target dose of 30 mg/day) or placebo in a 1 ∶ 1 ratio. 186 people, 181 of whom were over the age of 60, having probable AD with clinically significant agitation were recruited from September 2009 to January 2013. After the FDA safety communication about citalopram, ECG was added to the required study procedures before enrollmen

SUBMITTER: Drye LT 

PROVIDER: S-EPMC4051660 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature